Spots Global Cancer Trial Database for Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma

Official Title: An Open-Label Phase II Study of the Safety and Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Study ID: NCT00375791

Conditions

Multiple Myeloma

Interventions

perifosine

dexamethasone

Study Description

Brief Summary: This is a phase 2 study of perifosine in patients with multiple myeloma. Patients will receive perifosine 150 mg at bedtime (qhs) daily. Patients will be assessed by serum and/or urine-electrophoresis at least every 3 weeks.

Detailed Description: Treatment: Patients will take three 50 mg tablets of perifosine qhs daily with food. All patients should continue therapy unless disease progression is documented on two occasions at least 1 week apart. Progressing patients will have dexamethasone 20 mg twice per week added to the perifosine. Patients who experience toxicity may continue on treatment with doses delayed or reduced. Evaluations: Serum and/or urine-electrophoresis will be evaluated for progression or response at 3 week intervals. This study will enroll a total of up to 64 patients.